Biotech IPO activity increases by 15% in Q3 2026 vs Q2 2026

Market overview

Odyssey's successful IPO could encourage more biotech firms to go public, reflecting improving market conditions. A 15% increase in IPO activity would validate the sector's recovery and investor appetite.

event prediction market

Implied probability (Yes)

65%

Source: user-generated

More event markets

• Will HCAC announce LOI by 2026-12-31? — 25% Yes
• Will PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) (CIK 0001350156) file a follow-up 10-Q amendment within 90 days? — 25% Yes
• Will Venyra announce a strategic partnership by 2026-12-31? — 60% Yes
• Will the CEO's line of credit be fully drawn? — 85% Yes
• Will enGene announce a new partnership or licensing deal before Q1 2027? — 50% Yes
• Will Where Food Comes From, Inc. (WFCF) (CIK 0001360565) file a follow-up 10-Q amendment within 90 days? — 25% Yes
• Will Rubrik, Inc. (RBRK) (CIK 0001943896) file a follow-up 10-Q amendment within 90 days? — 25% Yes
• Will Pharma-Bio Serv, Inc. (PBSV) (CIK 0001304161) file a follow-up 10-Q amendment within 90 days? — 25% Yes

Browse all event markets →